Key Highlights

  • Summit Therapeutics shares closed up 17% at $17.13.
  • Partner Akeso reported Chinese Phase 3 results showing ivonescimab improved survival compared to Merck's Keytruda in lung cancer patients.
  • The full data set is anticipated on September 15.
  • The global HARMONi-3 trial readout is slated for late 2026.

Summit Therapeutics Inc. (NASDAQ: SMMT) shares closed up 17% at $17.13 following partner Akeso's report that Chinese Phase 3 results for ivonescimab demonstrated improved survival compared to Merck's Keytruda in lung cancer patients.

What Happened

While the full data set is anticipated on September 15, the outcome bolsters ivonescimab's outlook ahead of the global HARMONi-3 trial readout slated for late 2026, with market attention remaining focused on the scale of efficacy and safety profile.

Market Reaction

Shares rose sharply as investors responded to the topline survival benefit disclosed by Akeso, even ahead of the full data presentation.

Outlook

The full Chinese Phase 3 data set, expected September 15, and the global HARMONi-3 trial readout, slated for late 2026, represent the next major disclosed milestones for ivonescimab.